Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Q2 Revenues Slump, Losses Jump

NEW YORK, July 25-CuraGen today reported sharply decreased revenues and doubled net losses for the second quarter of 2002.

 

As a result of CuraGen's move away from service collaborations and toward proprietary drug development, revenues slumped from $6.2 million in Q2 of 2001 to $3.7 million in the recently concluded quarter, a decline of 40 percent.

 

Net losses climbed from $10.3 million in the second quarter of last year ($0.21 per share) to $22 million ($0.45 per share) in the equivalent period this year.

 

R&D expenses climbed 36 percent to $22.2 million.

 

The company also said that it had expanded its obesity and diabetes drug development collaboration with Bayer. In this partnership, CuraGen will apply proteomics techniques to identify drug targets, and the partners will co-develop and co-commercialize promising compounds.

 

CuraGen is based in New Haven, Conn. For more details, see the company report.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.